On Wednesday, the US Supreme Court agreed to hear a case centered around the access to mifepristone, a drug commonly used for abortions and miscarriages. The case has been navigating through the US Court of Appeals for the Fifth Circuit, with the court previously permitting the drug’s continued availability during the legal proceedings.
The American Association of Pro-Life Obstetricians & Gynecologists and various other anti-abortion organizations and physicians led the contention against the use of mifepristone. These groups argue that the US Food and Drug Administration (FDA) overlooked safety concerns in approving the drug and lifting restrictions. They claim that the FDA’s actions, in altering the medication’s safety measures in 2016 and permitting its mail distribution in 2021, amounted to a violation of the Administrative Procedure Act.
The plaintiffs’ injury claim states that they oppose being obliged to treat women who may confront emergency complications post-consuming mifepristone. This may enforce obligations on them to perform or complete abortions or otherwise get involved in the process leading to an abortion, which they assert goes against their moral beliefs and induces distress. In contrast, the FDA counters this allegation as far-reaching and “limitless.”
Previously in August, the Fifth Circuit Court of Appeals ruled in favor of the organizations and physicians, securing their standing under Article III of the US Constitution to sue the FDA. The court also held that the 2019 and 2020 modifications to safety measures violated the Administrative Procedure Act. Following this ruling, it is now the Supreme Court’s turn to reconsider whether the petitioners have standing and if the FDA’s actions in 2016 and 2021 were “arbitrary and capricious.”
The advent of mifepristone in the US came in 1994 when it was developed by French pharmaceutical company, Roussel Uclaf. The company donated the US patent to the Population Council, a non-profit entity, which then requested FDA approval for the drug as part of a two-drug abortion regimen in 1996. The American Association of Pro-Life Obstetricians and Gynecologists had previously filed citizen petitions against the drug in 2002 and 2019.
Following the US Supreme Court’s 2021 decision in Dobbs v. Jackson Women’s Health Organization which overturned the landmark abortion-rights case Roe v. Wade, the use and merit of the abortion pill have become heated topics of debate. Transcending beyond the medical domain, the consequences of further abortion access restrictions are anticipated to exacerbate existing racist and discriminatory law enforcement practices, as noted by reproductive rights organization Guttmacher.
The case is to be heard by the US Supreme Court this term, with a potential decision emerging by summer 2024.
Read the original article here.